Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3693-8448
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.04 million
Profitability
Miscellaneous
Employees17
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions
What is Galmed Pharmaceuticals' stock symbol?
Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."
How were Galmed Pharmaceuticals' earnings last quarter?
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) announced its earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. Galmed Pharmaceuticals had a negative return on equity of 12.23% and a negative net margin of 423.62%. View Galmed Pharmaceuticals' Earnings History.
When is Galmed Pharmaceuticals' next earnings date?
What price target have analysts set for GLMD?
7 brokerages have issued 1 year target prices for Galmed Pharmaceuticals' shares. Their forecasts range from $20.00 to $59.00. On average, they anticipate Galmed Pharmaceuticals' share price to reach $35.75 in the next twelve months. This suggests a possible upside of 456.9% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.
What is the consensus analysts' recommendation for Galmed Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.
What are Wall Street analysts saying about Galmed Pharmaceuticals stock?
Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value S/O as of Aramchol – NASH (U.S.) 55.0% $20.05 $36.43 Shares outstanding 21,113 Aramchol – NASH (EU) 40.0% $5.33 $13.31 Current share price $7.11 Discount rate 14.0% Cash beyond 12 months $2.58 $2.58." (5/8/2019)
- 2. Maxim Group analysts commented, "Galmed reported 1Q19 with a net loss of ($3.5M) and ended the period with $86.6M in cash." (5/7/2019)
- 3. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $59 12-month PT on Galmed Pharmaceuticals following earnings from 4Q18/2018. The company announced plans to have an end-of-Phase 2b meeting with the FDA during March, with the goal of initiating the Phase 3 ARMOR study in late-2Q19/early-3Q19. Minutes from this meeting and finalized Phase 3 trial design plans could be important data points in 2019. Additionally, Galmed will present a poster on Aramchol improvement in liver glucose homeostasis in NASH at EASL on 4/13 (link)." (3/13/2019)
- 4. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (2/28/2019)
Has Galmed Pharmaceuticals been receiving favorable news coverage?
Press coverage about GLMD stock has trended somewhat positive recently, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Galmed Pharmaceuticals earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Galmed Pharmaceuticals' key competitors?
Some companies that are related to Galmed Pharmaceuticals include Dermira (DERM), Basilea Pharmaceutica (BPMUF), Revance Therapeutics (RVNC), Akorn (AKRX), GlycoMimetics (GLYC), Urogen Pharma (URGN), CytomX Therapeutics (CTMX), Synthorx (THOR), MediciNova (MNOV), NuCana (NCNA), Flexion Therapeutics (FLXN), Corbus Pharmaceuticals (CRBP), Vital Therapies (VTL), Milestone Pharmaceuticals (MIST) and Corium International (CORI).
What other stocks do shareholders of Galmed Pharmaceuticals own?
Who are Galmed Pharmaceuticals' key executives?
Galmed Pharmaceuticals' management team includes the folowing people:
- Mr. Allen Baharaff, Chairman, CEO & Pres (Age 54)
- Mr. Yohai Stenzler, CFO & Controller (Age 36)
- Mr. Guy Nehemya, Chief Operating Officer (Age 34)
- Dr. Liat Hayardeny, Chief Scientific Officer (Age 52)
- Dr. Tali Gorfine, Chief Medical Officer (Age 49)
Who are Galmed Pharmaceuticals' major shareholders?
Galmed Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Ibex Investors LLC (3.14%), First Midwest Bank Trust Division (0.85%), ARK Investment Management LLC (0.26%), JPMorgan Chase & Co. (0.18%), Delek Group Ltd. (0.10%) and Morgan Stanley (0.03%).
Which institutional investors are selling Galmed Pharmaceuticals stock?
GLMD stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division and Morgan Stanley.
Which institutional investors are buying Galmed Pharmaceuticals stock?
GLMD stock was acquired by a variety of institutional investors in the last quarter, including Ibex Investors LLC, JPMorgan Chase & Co., Delek Group Ltd. and ARK Investment Management LLC.
How do I buy shares of Galmed Pharmaceuticals?
Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Galmed Pharmaceuticals' stock price today?
One share of GLMD stock can currently be purchased for approximately $6.42.
How big of a company is Galmed Pharmaceuticals?
Galmed Pharmaceuticals has a market capitalization of $134.94 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.
What is Galmed Pharmaceuticals' official website?
How can I contact Galmed Pharmaceuticals?
Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.
MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
